Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up over the course of the 2 cataract surgeries, approximately taking 3 months including preoperative and postoperative care.
Awards & highlights
Study Summary
This trial evaluates a novel eye shield to see if it can be used in post-surgery care to improve patient satisfaction and compliance.
Who is the study for?
This trial is for adult patients planning to have cataract surgery on both eyes within 3 months. It's not for pregnant individuals or those having more complex eye surgeries beyond standard cataract removal and lens placement.Check my eligibility
What is being tested?
The study compares a new type of eye shield with reusable adhesive anchors against the standard Alcon Eye Shield used after cataract surgery. Patients will try both shields, one after each eye's surgery, and share their preferences.See study design
What are the potential side effects?
Since this trial involves non-invasive protective eyewear rather than medication, traditional side effects are not applicable. However, discomfort or skin irritation from the adhesive might occur.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ over the course of the 2 cataract surgeries, approximately taking 3 months including preoperative and postoperative care.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~over the course of the 2 cataract surgeries, approximately taking 3 months including preoperative and postoperative care.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility of use of a new eye shield versus regular eye shield.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Novel prototype eye shield after surgeryExperimental Treatment1 Intervention
Novel prototype eye shield after surgery
Group II: Regular eye shield after surgeryActive Control1 Intervention
Alcon eye shield after surgery
Find a Location
Who is running the clinical trial?
Augusta UniversityLead Sponsor
210 Previous Clinical Trials
85,008 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Male or Female cataract surgery patients who are 18 years of age or older, with an intended plan to remove both eye cataracts through phacoemulsification and intraocular lens placement sequentially within a 3-month period.
Research Study Groups:
This trial has the following groups:- Group 1: Regular eye shield after surgery
- Group 2: Novel prototype eye shield after surgery
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any vacancies remaining for individuals to take part in this clinical trial?
"The most recent information from clinicaltrials.gov reveals that this research is actively accepting candidates. It was initially shared on June 15th, 2019 with the latest update posted on July 14th of the same year."
Answered by AI
How many participants have signed up for this clinical experiment?
"Affirmative. Per the information hosted on clinicaltrials.gov, this study is actively recruiting participants with an initial posting date of June 15th 2023 and last updated July 14th 2023. The trial seeks to include a total of twenty individuals at one site."
Answered by AI
Share this study with friends
Copy Link
Messenger